Saturday 17 October 2026
Export PTCT’s income statement to Excel — free account
PTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024. In the quarter to June 2026, revenue grew 101.6%, EPS grew 221.7%, free cash flow grew 295.7% and total debt rose 21.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
59.24
1.75
−2.87%
Follow PTCT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(124.24%) | (104.75%) | 101.97% | 20.64% | |
Piotroski F-Score |
7 | 7 | 1 | 2 | |
| 33.51% | 29.66% | (6.76%) | (1.30%) | ||
ROIC |
90.05% | 121.13% | (6.74%) | 15.16% | |
Return on Tangible Assets |
62.72% | 50.16% | (13.50%) | (2.02%) | |
Average Days of Receivables |
41.66 | 38.30 | 97.05 | 86.49 | |
Free Cash Flow per Share |
5.69 | 8.83 | (5.85) | (3.62) | |
Free Cash Flow |
446.32 | 702.41 | (482.67) | (300.25) | |
Capital Expenditures |
(269.15) | (8.79) | (264.72) | (269.74) | |
| Other line items | |||||
Cash ROIC |
11.40% | 16.19% | (11.16%) | (6.03%) | |
Accounts Receivable Turnover |
8.83 | 10.18 | 3.84 | 4.64 | |
Accounts Payable Turnover |
0.18 | 0.14 | 0.20 | 0.20 | |
Inventory Turnover |
1.28 | 0.91 | 1.28 | 1.13 | |
Average Days of Payables |
1,963.70 | 2,960.12 | 1,837.65 | 1,973.96 | |
Days of Inventory on Hand |
341.30 | 618.36 | 443.59 | 471.76 | |
Tax Rate |
0.01 | (0.02) | (0.21) | (0.43) | |
Research and Development Expense of Revenue |
25.12% | 26.31% | 54.06% | 42.95% | |
Selling, General and Administrative Expense of Revenue |
18.83% | 20.06% | 42.60% | 34.47% | |
Share Based Compensation of Revenue |
4.12% | 4.31% | 9.66% | 8.39% | |
Interest Coverage |
5.62 | 5.69 | (0.35) | 0.68 | |
Operating CF/Net income |
0.95 | 1.04 | 1.17 | 0.79 | |
Depreciation/Fixed assets |
3.12 | 0.40 | 0.55 | 0.72 | |
Capex/Depreciation |
(1.51) | (0.40) | (9.05) | (7.25) | |
Revenue per Share |
22.67 | 21.76 | 10.02 | 12.15 | |
Operating CF per Share |
9.12 | 8.94 | (2.64) | (0.37) | |
Capex per Share |
(3.43) | (0.11) | (3.21) | (3.25) | |
Capex to Sales |
0.15 | 0.01 | 0.32 | 0.27 |
Columns are period end dates